Top Pharma Stories for November
Extractables and leachables are the focus of this month’s issue of PTE Digital. E&Ls can lead to quality defects and more, and must be considered by pharma manufacturers. Other top stories this issue include quality by design, biosimilar mAbs and Alzheimer’s Disease. More... |
 |
|
| |
Growing Area of Concern for Pharma Companies
Extractables and leachables are a growing area of concern for pharmaceutical regulators. Our roundtable of industry experts looks at the common types of E&Ls and how pharmaceutical manufacturers are tackling the challenges with analytical testing technologies More... |
 |
|
| |
Europe's Alzheimer's R&D Crisis
The pharmaceutical industry is under pressure to deliver new therapies for Alzheimer’s disease, but regulatory bureaucracy in Europe coupled with the demand for lower-priced medicines continues to hinder efforts in innovation. More... |
 |
|
| |
|
| |
Pharma News Roundup
If you’ve missed out on some of the top pharma news stories recently then our news roundup will update you. Highlights include Novasep’s chromatography plant, Europe’s first facility for cell-based therapeutics, and more. More... |
 |
|
| |
Pharma News Roundup
If you’ve missed out on some of the top pharma news stories recently then our news roundup will update you. Highlights include Novasep’s chromatography plant, Europe’s first facility for cell-based therapeutics, and more. More... |
|
|
| |
Pharma News Roundup
If you’ve missed out on some of the top pharma news stories recently then our news roundup will update you. Highlights include Novasep’s chromatography plant, Europe’s first facility for cell-based therapeutics, and more. More... |
|
|
| |
Pharma News Roundup
If you’ve missed out on some of the top pharma news stories recently then our news roundup will update you. Highlights include Novasep’s chromatography plant, Europe’s first facility for cell-based therapeutics, and more. More... |
|
|
|
|
Eliminate Ghost Peaks in UHPLC
- Shimadzu has introduced the Ghost Trap DS-HP Series Columns.
- Shimadzu has introduced the Ghost Trap DS-HP Series Columns.
- the Ghost Trap™ DS-HP
- Shimadzu has introduced the Ghost Trap DS-HP Series Columns.
- Series Columns which are designed.
 Read more
|
|
|
Eliminate Ghost Peaks in UHPLC
- Shimadzu has introduced the Ghost Trap DS-HP Series Columns.
- Shimadzu has introduced the Ghost Trap DS-HP Series Columns.
- the Ghost Trap™ DS-HP
- Shimadzu has introduced the Ghost Trap DS-HP Series Columns.
- Series Columns which are designed.
Read more |
|
|
|
|
Eliminate Ghost Peaks in UHPLC
Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.
Read more |
|
|
Eliminate Ghost Peaks in UHPLC
Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.
Read more |
|
|
|
|
Eliminate Ghost Peaks in UHPLC
Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.
Read more |
|
|
Eliminate Ghost Peaks in UHPLC
Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.
Read more |
|
|
|
|
Eliminate Ghost Peaks in UHPLC
Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.
Read more |
|
|
Eliminate Ghost Peaks in UHPLC
Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.
Read more |
|
|
|
|
|
| Concerns have recently been raised about the safety of confidential data at FDA. Do you think regulators are doing enough to protect confidential data? |
|
This week we would like to know...
2012 has been touted as a crucial year of the so-called patent cliff. Do you think the impact of patent expiries has been better or worse than expected?
|
|
|
Contact Us
Click here to contact editorial.
Click here to contact sales. |
| Contact Us |
Click here to contact editorial.
Click here to contact sales. |
|
